Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma

The objective of this study is to evaluate the efficacy and safety profiles of the targeted medications, bevacizumab and cetuximab, in combination with cytostatic drugs in patients with locally advanced or metastatic pancreatic cancer. In this retrospective phase 2 study, a total of 59 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Tai, Cheng-Jeng, Huang, Ming-Te, Wu, Chih-Hsiung, Wang, Chien-Kai, Tai, Chen-Jei, Chang, Chun-Chao, Hsieh, Cheng-I., Chang, Yu-Jia, Wu, Chang-Jer, Kuo, Li-Jen, Wei, Po-Lei, Chen, Ray-Jade, Chiou, Hung-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839806/
https://www.ncbi.nlm.nih.gov/pubmed/27082562
http://dx.doi.org/10.1097/MD.0000000000003259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839806/
https://www.ncbi.nlm.nih.gov/pubmed/27082562
http://dx.doi.org/10.1097/MD.0000000000003259

Ejemplares similares